211 related articles for article (PubMed ID: 28649874)
1. A web application for evaluating Phase I methods using a non-parametric optimal benchmark.
Wages NA; Varhegyi N
Clin Trials; 2017 Oct; 14(5):553-557. PubMed ID: 28649874
[TBL] [Abstract][Full Text] [Related]
2. A web tool for designing and conducting phase I trials using the continual reassessment method.
Wages NA; Petroni GR
BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
[TBL] [Abstract][Full Text] [Related]
3. A benchmark for dose finding studies with continuous outcomes.
Mozgunov P; Jaki T; Paoletti X
Biostatistics; 2020 Apr; 21(2):189-201. PubMed ID: 30165594
[TBL] [Abstract][Full Text] [Related]
4. Performance of two-stage continual reassessment method relative to an optimal benchmark.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
[TBL] [Abstract][Full Text] [Related]
5. A benchmark for dose-finding studies with unknown ordering.
Mozgunov P; Paoletti X; Jaki T
Biostatistics; 2022 Jul; 23(3):721-737. PubMed ID: 33409536
[TBL] [Abstract][Full Text] [Related]
6. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
[TBL] [Abstract][Full Text] [Related]
7. AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.
Wheeler GM; Sweeting MJ; Mander AP
PLoS One; 2016; 11(7):e0159026. PubMed ID: 27403961
[TBL] [Abstract][Full Text] [Related]
8. Simple benchmark for complex dose finding studies.
Cheung YK
Biometrics; 2014 Jun; 70(2):389-97. PubMed ID: 24571185
[TBL] [Abstract][Full Text] [Related]
9. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
10. np1: a computer program for dose escalation strategies in phase I clinical trials.
Kramar A; Houédé N; Paoletti X
Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
[TBL] [Abstract][Full Text] [Related]
11. Up-and-down designs for phase I clinical trials.
Liu S; Cai C; Ning J
Contemp Clin Trials; 2013 Sep; 36(1):218-27. PubMed ID: 23856381
[TBL] [Abstract][Full Text] [Related]
12. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
13. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
14. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Rossoni C; Bardet A; Geoerger B; Paoletti X
Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
[TBL] [Abstract][Full Text] [Related]
15. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
16. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
17. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
18. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
19. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
20. Shift models for dose-finding in partially ordered groups.
Horton BJ; Wages NA; Conaway MR
Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
